INTRODUCTION
Magnesium (Mg) deficiency has been implicated in the causation of migraine headaches on theoretical and experimental grounds [ 1-31. Anecdotal observations [4, 51 and one double-blind, placebocontrolled trial [6] suggest that oral Mg supplementation is helpful in treating some patients with migraine headaches. One study [7] reported that total serum Mg (TMg) levels in patients with migraine and tension-type headaches were decreased more during an attack than between attacks. Two other studies [6, S] showed normal TMg levels between migraine attacks. In one of these studies [S], decreased Mg concentration was found in erythrocytes, while in the other [6] , Mg concentration in lymphocytes and polymorphonuclear cells was decreased but was normal in erythrocytes. Decreased Mg content in mononuclear cells in migraine patients with and without aura during an interictal period has also been reported [9] . One group [lo] found that serum and intracellular Mg levels of patients with migraine with and without aura and familial hemiplegic migraine were not different from those of control subjects.
Mg in cells and blood (including plasma and serum) exists in free or ionized, bound and complex states; the total Mg consists of all three fractions. Recently, it has become possible to rapidly and accurately measure serum-free, ionized Mg (IMg2+) which is the biologically active form of Mg [ll, 123. Using this method we have found significantly lower levels of IMg2+ but not TMg in patients with acute migraine headaches than in normal control subjects [13] . In this study we test the hypothesis that an intravenous infusion of magnesium sulphate (MgSO,) will reduce headache pain in patients with an acute migraine headache who have low serum levels of IMg2+.
METHODS
Forty consecutive patients (3 men and 37 women) who presented with an acute migraine but who did not have renal, cardiac or other medical problems were enrolled in this study after informed consent was obtained. The protocol was approved by our hospital's Institutional Review Board. Patients were told that some patients with headaches have been found to have lower Mg levels, and that this study attempts to establish whether giving an injection of Mg relieves headaches in such patients. They were also told that, since we did not want to bias the outcome of the study, we were giving Mg to all volunteers without prior knowledge of their Mg level. The diagnosis of acute migraine headache was established using the International Headache Society's classification [ 141. Seven patients had migraine with aura and 33 migraine without aura. Their mean age was 39.8 years (range 23-58 years).
Immediately before the Mg infusion a blood sample for serum IMg", TMg and ionized calcium (ICa2+) was drawn. The laboratory personnel and the physician were blinded to the study. The blood samples were not accompanied by any clinical information, and the clinician who administered the infusion received the laboratory results days after the headache treatment and evaluation were completed. One gram of MgSO, in a 10% solution was given intravenously over 5min. Patients remained in a recumbent position during the infusion and for 5min after the infusion. Headache intensity was measured on a verbal 1 to 10 scale before and 15 min after the infusion. The recurrence or worsening of a headache within the following 24h was determined using the verbal 1 to 10 scale in a telephone interview. A greater than 50% reduction of pain intensity lasting at least 24 h was considered a positive response. The clinical response was correlated with the levels of IMg", TMg and ICa2+, and with percentage IMg" and lCa2+/IMg2+ ratios. The clinical response was also categorized by levels of IMg2+ below and above 0.54mmol/l, a level selected to maximize the difference between the groups.
Mean values 1 S E M of laboratory measures were calculated and compared for statistical significance by analysis of co-variance and Tukey's honest difference contrast test, where appropriate. The difference in frequency of response was evaluated by exact contingency table analysis [l5]. A P value <0.05 was considered significant. Correlations were obtained using the Spearman rank correlation coefficient. These data were also compared with identical data previously obtained from 60 normal control subjects [12] .
RESULTS
All patients reported a flushed feeling during the infusion and 12 patients felt lightheaded for a few minutes upon sitting up after the infusion. No other side-effects were noted. Patients with positive responses expressed satisfaction with the degree and speed of relief of pain and migraine-associated symptoms.
Of the 40 patients, 35 (87.5%) had a reduction of pain of 50% or more 15min after the infusion. This included nine patients who had complete relief. In 21 of these 35 patients, at least this degree of improvement or complete relief persisted for 24 h or more (positive response). Of these 21 patients with a positive response, 18 had serum IMg'+ levels below 0.54mmol/l. Of the 19 patients without a positive response, 16 had IMg2+ levels of 0.54mmol/l or above (Fig. 1) . Thus, 18 of 21 patients (86%) with a positive response and 3 of 19 patients (16%) without this response had IMg2+ levels of 0.54mmol/l or below. The likelihood of experiencing significant relief among patients with IMg2+ levels below 0.54 mmol/l was 28 times greater than for patients with IMg2+ levels of 0.54mmol/l or more (odds ratio =27.9, P <0.0001, 95% confidence interval 5.4-194.4). The sensitivity and specificity of IMg2+ (above and below 0.54) in predicting response was 85%, as were the predictive values of a positive and negative test result. Table 1 shows mean laboratory values. Table 2 shows the difference in laboratory values between responders and non-responders adjusting for sex. Responders had significantly lower levels of IMg". TMg levels were also lower in responders, but did not reach statistical significance ( P <0.071) ( Table 2 ). When normal control subjects were included, responders had significantly lower IMg2+ and TMg levels than either non-responders or control subjects (Fig. 2) . ICaZ+ levels were not significantly different in responders and nonresponders or from values found in normal control subjects. Patients had a significantly higher mean ICa2+/IMg2+ and lower percentage IMg2+ than normal control subjects. Within the responders and non-responders, correlations of IMg2 + with TMg and ICa2+ were similar ( Table 3) .
The mean duration of illness in responders was 210 months (range 6-624 months), while in nonresponders it was 165 months (12-336 months). The mean duration of a usual attack in responders was 42h (4-72h) and 30h ( 4 7 2 h ) in non-responders. Mean attack frequency was 0.9 per week (once a year to three per week) in responders and 1.1 per week (once in 3 months to three per week) in non-responders.
DISCUSSION
Mg deficiency appears to be a common denominator in the leading theories of migraine pathogenesis. Current theories include vascular, 5-hydroxytryptamine and the lesser known theory of neurogenic inflammation [ 161. Primary or secondary abnormalities in Mg metabolism could play a causative role in the genesis of migraine headache according to any of these theories, since Mg is involved in control of vascular tone [17, 181, regulation of function of 5-hydroxytryptamine [19] and Nmethyl-D-aspartate receptors [ZO], nitric oxide production [21], substance P release [22] and catecholamine production and activity [23] .
IMgz+ levels are known to affect entry of Ca2+, intracellular ICa2 5-Hydroxytryptamine is known to be released from platelets during a migraine attack, and to be a potent cerebral vasoconstrictor and to promote nausea and vomiting. A lowering of IMg2+ and an elevation of the ICa2 +/IMg2+ ratio may increase affinity for 5-hydroxytryptamine cerebral vascular muscle receptor sites, potentiate cerebral vasoconstriction induced by 5-hydroxytryptamine and facilitate 5-hydroxytryptamine release from neuronal storage sites [18, 191 . 
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Resp vs nresp , lo I -0.836 9.381 A Mg-deficiency-induced state has recently been shown experimentally to result in significant generation and release of substance P into the bloodstream There was a very strong relationship between headache reduction and low IMg". Patients with low lMgZf were 28 times more likely to respond than those with high IMg" (P<O.Ol). However, this number probably overstates the magnitude of the association since the breakpoint of 0.54 mmol/l was selected to maximize the difference. We justified this post-hoc selection by the fact that this was the first study of its kind. Furthermore, there does appear to be a natural break in the distribution of the IMg" levels and we do know, on the basis of evaluation of several hundred patients with other diseases [ 121 that IMg2' levels below 0.54 mmol/l are most probably abnormal.
The sustained relief in 3 of 19 patients with high IMg2+ levels may reflect the placebo effect, which has been described in up to 452, of patients with migraine headaches. Lack of significant headache reduction in 3 of 21 patients with lower IMg" levels might be attributed to the probable multiple mechanisms involved in migraine headache causation. The predominance of women in our study exceeds what would be expected of the known distribution of migraine sufferers by sex. However, this reflects our patient population. It is an established fact that a higher proportion of women than men seek medical attention.
In conclusion, our findings suggest that Mg metabolism is disturbed in at least some patients with migraine headaches, and that infusion of 1 g of MgSO, relieves acute migraine attacks in patients with serum IMg" levels below 0.54 mmol/l. Since an lMg2+ level below or above 0.54mmol/l correctly predicted 85';/, of the subjects who did and did not benefit from intervention, this may be a clinically useful screening approach. Randomized, double-blind, placebo-controlled trials of Mg infusions for migraine headaches need to be performed.
